Advanced Cell Tech (ACTC) 0.0591 $ACTC
Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
ACCESSWIRE - Mon Apr 28, 8:07AM CDT
Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.
Advanced Cell Technology's Chief Scientific Officer Dr. Robert Lanza Named One of TIME Magazine's 100 Most Influential People in the World
Business Wire - Thu Apr 24, 9:41AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company's Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 TIME 100 annual list of the hundred most influential people in the world. The TIME 100 issue, containing the full list hits newsstands on Friday, April 25.
Terra Tech Corp. Releases Revenue Guidance of $7 Million for 2014
ACCESSWIRE - Wed Apr 23, 8:56AM CDT
Terra Tech Corp. (OTCQB: TRTC) recently released a corporate update and revenue guidance of $7,000,000 for the full year 2014.
Abattis Bioceuticals Corp. Enters Into Share Agreement with Experion
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, Abattis Bioceuticals Corp. (OTCPINK: ATTBF) share volume soared, with 1,166,632 changing hands, significantly higher than its three-month average
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
Advanced Cell Technology to Host Conference Call to Provide a Corporate Update
Business Wire - Tue Apr 01, 3:38PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it filed its annual report on Form 10-K for the year ended December 31, 2013. The Company will host a conference call on Thursday, April 3, 2014, at 8:30 a.m. EDT during which it will provide a corporate update.
New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties
Business Wire - Mon Mar 24, 3:55PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, and its collaborators reported today that it has discovered a new method to generate a potent and replenishable population of mesenchymal stem cells (MSCs) from pluripotent stem cells. The research appears online ahead of print in Stem Cell and Development, one of the top stem cells journals, published by Mary Ann Liebert, Inc. This new and proprietary population of pluripotent stem cell-derived MSCs displays potent immunomodulatory and therapeutic properties and has a greater than 30,000 fold proliferative capacity, relative to ordinary bone marrow-derived MSCs, the most commonly used source for MSCs in clinical trials. The paper is available free online at http://online.liebertpub.com/doi/abs/10.1089/scd.2013.0554.
OTC Daily Alert Stock Watch - Advanced Cell Technology, Inc.(OTCQB: ACTC)
WorldStockWire - Mon Mar 24, 3:31AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Advanced Cell Technology to Present at Regenenerative Medicine Investor Day March 26, 2014
Business Wire - Fri Mar 21, 3:00PM CDT
Advanced Cell Technology (ACTC) today announced that Edward Myles, Interim President, CFO & EVP of Corporate Development, will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Advanced Cell Technology Announces Change in Management
Business Wire - Wed Jan 22, 7:30AM CST
Advanced Cell Technology (OTC:ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position, effective immediately. The board has appointed the Company's CFO and Executive Vice President of Corporate Development, Edward Myles, as interim President. The board will initiate a search for a permanent CEO.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
Clearlake Capital Invests in PrimeSport
Marketwire - Wed Jan 08, 3:47PM CST
PrimeSport, Inc. ("PrimeSport" or the "Company"
and Clearlake Capital Group, L.P. (together with its affiliates, "Clearlake" today announced that Clearlake has acquired a majority stake in PrimeSport, a leading sports travel and entertainment management company.
Strategy Analytics: CES 2014: 56 percent of US consumers would buy UHD TV in next two years
PR Newswire - Wed Jan 08, 2:58PM CST
CES -- Strategy Analytics' new ConsumerMetrix survey carried out over the past few weeks with 2024 US consumers found very strong interest in UHD TV. 19 percent of people said they would be very likely to buy a UHDTV and 37 percent somewhat likely within the next two years. Only 24 percent said they would be unlikely to buy one.
New Year, New Codes 2014 CPT(R) Coding Updates; VitalWare Hosts Free Webinar Reviewing Significant Coding Changes
Marketwire - Tue Jan 07, 2:46PM CST
On January 14, 2014 and January 16, 2014, VitalWare will host complimentary hour-long webinars introducing and reviewing the significant changes in the 2014 CPT(R) and HCPCS code set updates.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Celtic Bank Hires Michael Caron as Vice President Business Development
PR Newswire - Tue Jan 07, 11:04AM CST
Celtic Bank is pleased to announce that Michael Caron has been hired as Vice President of Business Development in the Asset-Based Lending Group at Celtic Bank. Caron will be focused on business development of the bank's asset-based lending and factoring programs in the Northeast United States. Caron will report to Daniel Godfrey, Senior Vice President of Asset-Based Lending at Celtic Bank.
Cellceutix Corp. Reports Favorable Results on Trial of New Antibiotic
ACCESSWIRE - Mon Apr 28, 8:07AM CDT
Cellceutix Corp. (OTCQB: CTIX) enjoyed strong stock volume Apr. 25, with 180,001 shares changing hands.
Advanced Cell Technology's Chief Scientific Officer Dr. Robert Lanza Named One of TIME Magazine's 100 Most Influential People in the World
Business Wire - Thu Apr 24, 9:41AM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that the company's Chief Scientific Officer, Robert Lanza, MD, has been selected for the 2014 TIME 100 annual list of the hundred most influential people in the world. The TIME 100 issue, containing the full list hits newsstands on Friday, April 25.
Terra Tech Corp. Releases Revenue Guidance of $7 Million for 2014
ACCESSWIRE - Wed Apr 23, 8:56AM CDT
Terra Tech Corp. (OTCQB: TRTC) recently released a corporate update and revenue guidance of $7,000,000 for the full year 2014.
Abattis Bioceuticals Corp. Enters Into Share Agreement with Experion
ACCESSWIRE - Thu Apr 17, 9:00AM CDT
On Apr. 16, Abattis Bioceuticals Corp. (OTCPINK: ATTBF) share volume soared, with 1,166,632 changing hands, significantly higher than its three-month average
Global Glaucoma Pipeline Review, H1 2014
M2 - Tue Apr 08, 4:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/2tn556/glaucoma) has announced the addition of the "Glaucoma - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Glaucoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Glaucoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Glaucoma - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Glaucoma and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Glaucoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Glaucoma pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Alcon, Inc. - Allergan, Inc. - Advanced Cell Technology, Inc. - Santen Pharmaceutical Co., Ltd. - Kowa Company, Ltd. - Merz Pharma GmbH & Co. KgaA - Ono Pharmaceutical Co., Ltd. - Teva Pharmaceutical Industries Limited - Sun Pharmaceutical Industries Limited - InSite Vision Incorporated - Can-Fite BioPharma Ltd. - NicOx S.A. - Acadia Pharmaceuticals Inc. - NeoStem, Inc. - Handok Inc. - AC Immune SA - Upsher-Smith Laboratories, Inc. - Foamix Ltd. - Laboratoires Thea S.A. - Senju Pharmaceutical Co., Ltd. - Neurotech Pharmaceuticals, Inc. - Intellect Neurosciences, Inc. - SIFI S.p.A - Cancer Therapeutics CRC Pty Ltd - Mimetogen Pharmaceuticals Inc. - Icon Bioscience, Inc. - AUS Bio Limited - SK Biopharmaceuticals Co., Ltd. - Cellular Biomedicine Group, Inc. - China Grand Wuhan General Pharmaceutical Research Institute For more information visit http://www.researchandmarkets.com/research/2tn556/glaucoma
Advanced Cell Technology to Host Conference Call to Provide a Corporate Update
Business Wire - Tue Apr 01, 3:38PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB:ACTC), a leader in the field of regenerative medicine, announced today that it filed its annual report on Form 10-K for the year ended December 31, 2013. The Company will host a conference call on Thursday, April 3, 2014, at 8:30 a.m. EDT during which it will provide a corporate update.
New Mesenchymal Stem Cell Population from Human Pluripotent Stem Cells Displays Potent Immunomodulatory and Therapeutic Properties
Business Wire - Mon Mar 24, 3:55PM CDT
Advanced Cell Technology, Inc. ("ACT"; OTCBB: ACTC), a leader in the field of regenerative medicine, and its collaborators reported today that it has discovered a new method to generate a potent and replenishable population of mesenchymal stem cells (MSCs) from pluripotent stem cells. The research appears online ahead of print in Stem Cell and Development, one of the top stem cells journals, published by Mary Ann Liebert, Inc. This new and proprietary population of pluripotent stem cell-derived MSCs displays potent immunomodulatory and therapeutic properties and has a greater than 30,000 fold proliferative capacity, relative to ordinary bone marrow-derived MSCs, the most commonly used source for MSCs in clinical trials. The paper is available free online at http://online.liebertpub.com/doi/abs/10.1089/scd.2013.0554.
OTC Daily Alert Stock Watch - Advanced Cell Technology, Inc.(OTCQB: ACTC)
WorldStockWire - Mon Mar 24, 3:31AM CDT
OTC Daily Alert tracks stocks daily and is pleased to offer features on public companies. Investors can receive FREE Stock Alerts and company news and profiles by visiting OTC Daily Alert at the following: http://www.otcdailyalert.com
Advanced Cell Technology to Present at Regenenerative Medicine Investor Day March 26, 2014
Business Wire - Fri Mar 21, 3:00PM CDT
Advanced Cell Technology (ACTC) today announced that Edward Myles, Interim President, CFO & EVP of Corporate Development, will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City.
Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016
M2 - Wed Mar 12, 6:14AM CDT
Research and Markets (http://www.researchandmarkets.com/research/4lq46f/regenerative) has announced the addition of the "Concise Analysis of the United States Regenerative Medicine Market - Forecasts to 2016" report to their offering. There is a high demand for synthetic organ transplants in the market. Regenerative medicine helps in the development of artificial organs. The introduction of artificial organs for implantation is expected to encourage many vendors and research organizations to develop advanced stem cell products, therapies, and regenerative products. It will also help reduce the long organ waiting list. For instance, custom-made windpipe can be made using regenerative products within a week. The first ever implant of a synthetic trachea took place in June 2011. The synthetic trachea was made from minuscule plastic fibers and was covered in stem cells taken from a human bone marrow. Surgeons successfully implanted this synthetic trachea into a 36-year-old patient with late-stage tracheal cancer at Karolinska University Hospital in Stockholm. Thus, the use of synthetic organs in transplant surgeries is expected to have a positive impact on the growth of the market. According to the report, one of the main drivers of this market is the increasing prevalence of degenerative diseases. Regenerative products have helped in addressing the unmet needs of various disease areas. Another major driver of the market is the significant advances seen in R&D. Key Topics Covered: 1. Executive Summary 2. List of Abbreviations 3. Introduction 4. Market Research Methodology 5. Scope of the Report 6. Market Landscape 7. Vendor Landscape 8. Buying Criteria 9. Market Growth Drivers 10. Drivers and their Impact 11. Market Challenges 12. Impact of Drivers and Challenges 13. Market Trends 14. Key Vendor Analysis 15. Other Reports in this Series Companies Mentioned: - Advanced Cell Technology Inc. - Arteriocyte Inc. - Athersys Inc. - Baxter International Inc. - CryoLife - Cytori Therapeutics Inc. - Genzyme Corp. - Geron Corp. - InVivo Therapeutics - Inc. - Integra Life Sciences Holdings Corp. - Kensey Nash Corp. - Kinetic Concepts Inc. - Medtronic Inc. - NeoStem Inc. - Osiris Therapeutics Inc. - Osteotech Inc. - RTI Biologics Inc. - Stryker Corp. - Zimmer Holdings Inc. For more information visit http://www.researchandmarkets.com/research/4l...generative
Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020
M2 - Mon Mar 10, 7:45AM CDT
Research and Markets (http://www.researchandmarkets.com/research/gsw6jj/global_stem_cell) has announced the addition of the "Global Stem Cell Umbilical Cord Blood (UCB) Market to 2020" report to their offering. The market is expected to reach revenue of $56.4 billion by 2020, growing at CAGR of 33.4% during 2013 to 2020 The study observed that the global umbilical cord blood stem cell market is forecasted to reach market value over $11.5 billion in 2014 from $ 6.5 billion in 2012. Developments and approvals for novel cord blood stem cells therapies is expected to drive the market growth. The storage service market was valued at $7.4 billion in 2013. Increase in prevalence rate of chronic diseases such as cancer, diabetes, blood disease, immune disease, metabolic disease etc. has increased the need of cost effective and efficient way of treatment. However, cord blood stem cells have the potential to treat these chronic diseases effectively. These stem cells have special property of higher cell count in lower blood volume. Collection of these stem cells is much easier than other stem cells and could be stored in specialized preservation facilities called as Cord Blood Stem Cell Banks.Cord blood stem cells market is in its emerging phase. Significant applications of stem cells in the treatment of various disorders will be commercialized very soon as most of them are in the last phase of clinical trials. Patents for collection techniques and therapeutics methods are approved by respective government of developed countries however patents for UCB stem cells are comparatively less in developing economies. According to lead analyst Debbie Shields, the geographic analysis shows that the North American market for cord blood stem cell would account for approx. 44% of total revenue generated by the cord blood market in 2013. However, much expected growth is to occur in Asia-Pacific regions during the forecast period, because of growing demand for chronic disease treatments and widely increasing awareness levels. This report study offers updated review about major market players present in this market such as researcher based pharmaceutical companies and therapeutics services companies. Key Market Segments Global Stem cell UCB market by storage - Public cord blood banks - Private cord blood banks - Public Vs. Private UCB banks Global Stem cell UCB market by Diseases - Cancer/ Oncology diseases - Acute Leukemia - Chronic Leukemia - High Risk Solid Tumors - Myelodysplastic Syndrome - Blood diseases - Aplastic Anemia - Beta Thalassemia - Sickle Cell disease - Immune Disorders - Leukocyte Adhesion Deficiency - Hystiocytic Disorders - Wiskott-Aldrich - Metabolic Disorders - Krabbe Disease - Hurler Syndrome - Sanfilippo Syndrome - Other diseases - Osteopetrosis - Hemophagoyticlymphohistiocytosis Global Stem cell UCB market by Technology - Stem Cell Transplant - Autologous transplant - Allogenic transplant - Transplant Medicine - Regenerative Medicine - Others - Cord Blood Banking - Blood Transfusion - Cell Based Genetics Companies Mentioned - Advanced Cell Technology Inc. (USA) - Athersys Inc. - California Stem Cell - Cytori Therapeutics Inc. - Geron Corporation - Mesoblast Limited - NeoStem Inc. - Opexa Therapeutics Inc. - Osiris Therapeutics - Pluristem Therapeutics Inc. For more information visit http://www.researchandmarkets.com/research/gs..._stem_cell
Global Cell Therapy Market & Pipeline Insight Research Report
M2 - Tue Mar 04, 3:02AM CST
Research and Markets (http://www.researchandmarkets.com/research/5kmmgq/global_cell) has announced the addition of the "Global Cell Therapy Market & Pipeline Insight" report to their offering. Research in cell therapy is transforming the future of medicine. As the life of a human being begins as a cell, these cells undergo a highly complex set of events and finally those few stems become capable of self-renewal and differentiation and develop into the specialized cells in the body. Cell therapy research also offers significant potential for restructuring the method of medical practice. Over the past 3-5 years, a more complex therapeutic modality has been is emerging as cell therapies which have been developed to treat diseases which are not amenable to treatment with more classical pharmaceutical or biopharmaceutical products. This market offers the promise of successfully regenerating damaged tissues and organs in the body by replacing the damaged tissue and/or by stimulating the body's own repair mechanisms to heal previously irreparable tissues. With their rising popularity, these therapies are becoming more cost effective and efficient. The global market for cell therapy was valued at close to USD 2.5 Billion in 2012. With continuous advances and developments in this field of medicine, the global cell therapy market is expected to grow at a high rate of 20-22% to reach approximately USD 8 Billion by 2018. Several products and technologies of cell-based therapies are in the R&D pipeline are expected to enter the market during the forecast period, thus resulting in an increased growth rate. It is most likely that the new improved technologies would revolutionize the area of bio-pharma and personalized medicine. Development of sophisticated automation devices for cell expansion and culture process for use in the treatment is one of the emerging trends of ACT market. With the cell-based therapies growing by leaps and bounds, it is expected that the future years would witness significant advancements in technology in the cell therapy market. Increasing incidence of diseases along with lack of adequate effective treatment for these diseases is most likely to drive the cell therapy technology in developed and developing nations. Among the emerging trends of the global market, the most prominent one is the development of sophisticated automation devices for cell expansion and culture process which could be used in the treatment of life threatening diseases. Global Cell Therapy Market & Pipeline Insight Report Highlights & Findings: - Introduction to Cell therapy - Global Cell Therapy Market Overview - Global Cell Therapy Market Dynamics - Cell Therapy Pipeline by Phase, Country & Target Indications - Cell Therapy Drugs in Pipeline: More Than 200 - Highest Number of Drugs in Preclinical Stage: 73 - Number of Drugs in Phase I/II Stage: 35 - Key Market: US - Majority Cell therapies For Cancer Treatment Companies Mentioned - Advanced Cell Technology - Amgen - California Stem Cell - Celgene Corporation - Cytomedix - Fibrocell Science - Genzyme - NeoStem - Novartis - Stemedica Cell Technologies For more information visit http://www.researchandmarkets.com/research/5k...lobal_cell About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Advanced Cell Technology Announces Change in Management
Business Wire - Wed Jan 22, 7:30AM CST
Advanced Cell Technology (OTC:ACTC) today announced that Gary Rabin will leave the Chief Executive Officer position, effective immediately. The board has appointed the Company's CFO and Executive Vice President of Corporate Development, Edward Myles, as interim President. The board will initiate a search for a permanent CEO.
2013 Report on the International Regenerative Medicine Markets
M2 - Mon Jan 13, 8:07AM CST
Research and Markets (http://www.researchandmarkets.com/research/3gvqj4/regenerative) has announced the addition of the "2013 Report on the International Regenerative Medicine Markets" report to their offering. Astounding new advancements in the ability to repair or replace damaged human tissue and organ functions are being made. Whereas before, remedies for damaged tissue or organ functions due to congenital deformities, injuries, diseases or simple wear-and-tear relied upon either the body's ability to repair itself (or not), or a surgeon's skilled hands. Now, the area of regenerative medicine promises to revolutionize humanity's ability to remediate countless physical maladies that have perpetually afflicted humans and other animals. Compared to a select few life forms--like the starfish--man-made solutions for tissue repair and organ replacement haven't come close to nature's solutions. And where there once was no solution even offered by nature, researchers are now at the cusp of overcoming such limitations by "2013 Report on the International Regenerative Medicine Markets", enables the reader gain in-depth knowledge about ongoing tissue engineering and stem cell therapy research programs carried out in universities and other research centers. Moreover, this analysis profiles the leading companies developing regenerative medicine solutions. Key Topics Covered: 1. Overview 2. Regenerative Medicines: An Overview of Segments 3. Regenerative Medicine: The Next Evolution of Medical Treatment 4. Recent Advances in Regenerative Medicine and Stem Cell Research 5. Stem Cell Industry Highlights 6. Regenerative Medicines: A Brief Update from Selected Countries 7. Market Analysis for Regenerative Medicine Sector 8. Stem Cell Industry 9. Business Models and Requirements for a Successful Regenerative Medicine Industry 10. Company Profiles Companies Mentioned: - Aastrom Biosciences, Inc. - Advanced Cell Technology, Inc. (ACT) - Aldagen, Inc. - BeFutur Biotechnologies - Cardio BioSciences - CardioPolymers, Inc. - Develogen AG - Effector Cell Institute, Inc (ECI) - Epistem plc - FivePrime Therapeutics, Inc. - Forticell Bioscience, Inc. - Geron Corporation - Hydra Biosciences, Inc. - Intercytex Group plc - Japan Tissue Engineering, Co., Ltd. - Karocell Tissue Engineering AB - LifeCell - MaxCyte, Inc. - Mesoblast Ltd. - NanoCor's Products - Olympus Terumo Biomaterials Corporation - Pervasis Therapeutics, Inc. - RegeneRx - SyntheMed, Inc. - Thermogenesis Corp. - t cure GmbH For more information visit http://www.researchandmarkets.com/research/3g...generative
Clearlake Capital Invests in PrimeSport
Marketwire - Wed Jan 08, 3:47PM CST
PrimeSport, Inc. ("PrimeSport" or the "Company"
and Clearlake Capital Group, L.P. (together with its affiliates, "Clearlake" today announced that Clearlake has acquired a majority stake in PrimeSport, a leading sports travel and entertainment management company. Strategy Analytics: CES 2014: 56 percent of US consumers would buy UHD TV in next two years
PR Newswire - Wed Jan 08, 2:58PM CST
CES -- Strategy Analytics' new ConsumerMetrix survey carried out over the past few weeks with 2024 US consumers found very strong interest in UHD TV. 19 percent of people said they would be very likely to buy a UHDTV and 37 percent somewhat likely within the next two years. Only 24 percent said they would be unlikely to buy one.
New Year, New Codes 2014 CPT(R) Coding Updates; VitalWare Hosts Free Webinar Reviewing Significant Coding Changes
Marketwire - Tue Jan 07, 2:46PM CST
On January 14, 2014 and January 16, 2014, VitalWare will host complimentary hour-long webinars introducing and reviewing the significant changes in the 2014 CPT(R) and HCPCS code set updates.
Esri's Location Platform Brings the Power of Place to Microsoft Dynamics CRM
PR Newswire - Tue Jan 07, 1:45PM CST
Esri today announced the release of an enhanced Esri Maps for Microsoft Dynamics CRM. The software adds new analytical perspectives for retailers across the omni-channel. From a single store to the entire supply-chain, users can collaborate to author and share analytical intelligence on customers, stores, products, markets, and the competition with a wealth of demographic data for 120 countries.
Celtic Bank Hires Michael Caron as Vice President Business Development
PR Newswire - Tue Jan 07, 11:04AM CST
Celtic Bank is pleased to announce that Michael Caron has been hired as Vice President of Business Development in the Asset-Based Lending Group at Celtic Bank. Caron will be focused on business development of the bank's asset-based lending and factoring programs in the Northeast United States. Caron will report to Daniel Godfrey, Senior Vice President of Asset-Based Lending at Celtic Bank.
